Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients



Status:Completed
Conditions:Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - 85
Updated:11/19/2017
Start Date:August 2011
End Date:May 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients

This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety
and tolerability in patients who have frequent flares of acute gouty arthritis.


Inclusion criteria:

- Compliance and completion of the canakinumab PFS core study

- Unchanged significant clinical medical history from entry into core study

Exclusion criteria:

- Physician judgment of unsuitability for the study

- Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may
apply
We found this trial at
0
sites